Abstract
Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.
Keywords: Checkpoint inhibitors, cytokines, HNSCC, immune system, immunotherapy, PD-1.
Graphical Abstract
Current Molecular Pharmacology
Title:Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
Volume: 9
Author(s): Salah Almokadem
Affiliation:
Keywords: Checkpoint inhibitors, cytokines, HNSCC, immune system, immunotherapy, PD-1.
Abstract: Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.
Export Options
About this article
Cite this article as:
Almokadem Salah, Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma, Current Molecular Pharmacology 2016; 9 (3) . https://dx.doi.org/10.2174/1874467208666150716120658
DOI https://dx.doi.org/10.2174/1874467208666150716120658 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Current Cancer Drug Targets Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Formulation Development and Evaluation of Transdermal 5-Fluorouracil Ethosomal Formulation through 2<sup>5-2</sup> Fractional Factorial Design
Drug Delivery Letters Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Letters in Drug Design & Discovery The Association of Chemotherapy and Radiotherapy in Squamous Cell Carcinoma of Anal Canal
Current Drug Therapy Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Current Topics in Medicinal Chemistry Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Receptor Selective Synthetic Retinoids as Potential Cancer Chemotherapy Agents
Current Cancer Drug Targets Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Current Signal Transduction Therapy Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design nMET, A New Target in Recurrent Cancer
Current Cancer Drug Targets Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Evaluation of Adhesion Force and Binding Affinity of Phytohemagglutinin Erythroagglutinating to EGF Receptor on Human Lung Cancer Cells
Current Medicinal Chemistry